【摘要】 目的观察普罗布考和辛伐他汀联合治疗对急性冠状动脉综合征(ACS)患者高敏C反应蛋白(hsCRP)和血脂的影响。方法将79例ACS患者随机分为单独治疗组(辛伐他汀20mg/d)和联合治疗组(普罗布考1g/d,辛伐他汀20mg/d)分别测量两组患者服药前和服药1个月时的血清hsCRP、血脂(TC、TG、LDL-C、HDL-C)水平。结果治疗1个月后两组患者血清hs-CRP、TC、TG、LDL-C、HDL-C水平均较入院时降低(P<0.01),但联合治疗组降低的幅度较单独治疗组大(P<0.05)。结论普罗布考和辛伐他汀联合治疗与单用辛伐他汀均能降低ACS患者血清hsCRP和血脂水平,可能起到抑制炎症反应、稳定冠状动脉粥样斑块的作用,加用普罗布考可能发挥进一步稳定斑块的作用。更多还原

【Abstract】 [Objective] To investigate the effects of Probucol combined with Simvastatin and Simvastatin only on serum lipid and high-sensitivity C-reactive protein (hs-CRP) levels after 1 month. [Methods] 79 ACS patients were assigned to Simvastatin only group (20 mg/d of simvastatin, n =39) or combined therapeutic group (20 mg/d of Simvastatin and 1.0 g/d of Probucol, n =40) in a randomized study. The levels of serum lipid and hs-CRP were detected before and after treatment. [Results] The levels of serum lipid and hs-CRP were significantly decreased in Simvastatin only group and combined therapeutic group (P <0.01), and those in combined therapy decreased even more markedly (P <0.05). [Conclusions] Both Simvastatin alone and Simvastatin combined Probucol can decrease the levels of serum lipid and hs-CRP in patients with ACS, which may reduce inflammatory reaction and stabilize plaque. Simvastatin combined with Probucol may have stronger effect on stabilizing plaque than Simvastatin alone.更多还原